Drug Trial Radar · NCT01264770
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Last checked: Nov 20, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
644
Actual
Start
Jan 2011
Primary completion
Oct 2012
Study completion Aug 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the improvements in signs and symptoms of rheumatoid arthritis (RA) for fostamatinib compared to placebo or adalimumab in patients who are Disease-Modifying anti-rheumatic drug (DMARD) naïve, DMARD intolerant or have had an inadequate response to DMARDs. The study will last for approximately six months
Conditions
- Rheumatoid Arthritis
Interventions
Fostamatinib and placebo injectionsDrug
Fostamatinib 100mg twice daily and placebo injection once every two weeks
Fostamatinib and placebo injectionsDrug
Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
Fostamatinib and placebo injectionsDrug
Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
Adalimumab and placebo of fostamatinibDrug
Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
Placebo of fostamatinib, fostamatinib, and placebo injectionsDrug
Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
Primary outcomes
What the sponsor says the trial is designed to measure.
- DAS28-CRP Score - Change From Baseline to Week 6 Compared to PlaceboTime frame: Baseline and 6 weeks
- DAS28-CRP Score - Change From Baseline to Week 24 Compared to AdalimumabTime frame: Baseline and 24 weeks
Locations
105 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Glendale, Arizona
Research Site
Mesa, Arizona
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Huntington Beach, California
Research Site
Long Beach, California
Research Site
Colorado Springs, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Daytona Beach, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Palm Harbor, Florida
Research Site
Pinellas Park, Florida
Research Site
Venice, Florida
Research Site
Chicago, Illinois
Research Site
South Bend, Indiana
Research Site
Bowling Green, Kentucky
Research Site
Elizabethtown, Kentucky
Research Site
Oxon Hill, Maryland
Research Site
Kalamazoo, Michigan
Research Site
Richmond Heights, Missouri
Research Site
Kalispell, Montana
Research Site
Nashua, New Hampshire
Research Site
Albuquerque, New Mexico
Research Site
Las Cruces, New Mexico
Research Site
Brooklyn, New York
Research Site
Charlotte, North Carolina
Research Site
Perrysburg, Ohio
Research Site
Duncansville, Pennsylvania
Research Site
Greenville, South Carolina
Research Site
Jackson, Tennessee
Research Site
Knoxville, Tennessee
Research Site
Memphis, Tennessee
Research Site
Austin, Texas
Research Site
Houston, Texas
Research Site
Mesquite, Texas
Research Site
Plano, Texas
Research Site
San Antonio, Texas
Showing 40 of 105 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.